Summary by Moomoo AI
EyePoint Pharmaceuticals, Inc. has been the subject of a Schedule 13G filing with the United States Securities and Exchange Commission, indicating a significant investment by TCG Crossover Fund II, L.P., TCG Crossover GP II, LLC, and Chen Yu. The filing, dated October 31, 2024, reveals that the entities collectively hold 3,572,335 shares of EyePoint Pharmaceuticals' common stock, representing 5.2% of the company's class of securities. This stake is based on 68,096,174 shares of common stock outstanding, as reported in the company's prospectus supplement filed on October 30, 2024. TCG Crossover GP II, LLC, as the general partner of TCG Crossover Fund II, L.P., and Chen Yu, as the sole managing member of TCG Crossover GP II, LLC, may be deemed to share voting, investment, and dispositive power over these securities. The principal business office for the reporting persons is located in Palo Alto, California. The reporting persons have disclaimed beneficial ownership of the reported securities except to the extent of their pecuniary interest.
